X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
1. 2,3-dimethoxy-5-methyl-6-decaprenylbenzoquinone
2. Bio-quinone Q10
3. Co-enzyme Q10
4. Coenzyme Q10, (z,z,z,z,z,z,e,e,e)-isomer
5. Coenzyme Q10, Ion (1-), (all-e)-isomer
6. Coq 10
7. Coq10
8. Q-ter
9. Ubidecarenone
10. Ubiquinone 10
11. Ubiquinone 50
12. Ubiquinone Q10
13. Ubisemiquinone
14. Ubisemiquinone Radical
1. Ubidecarenone
2. 303-98-0
3. Ubiquinone-10
4. Coq10
5. Ubiquinone 50
6. Neuquinon
7. Ubiquinone Q10
8. Ubiquinone
9. Justquinon
10. Neuquinone
11. Emitolon
12. Heartcin
13. Inokiten
14. Terekol
15. Udekinon
16. Coenzyme Q-10
17. Vitamin Q
18. Coenzyme Q
19. Coenzyme-q10
20. Bio-quinone Q10
21. Unispheres Q 10
22. Co-enzyme Q10
23. Coenzyme Q 10
24. Puresorb Q 40
25. Aqua Q10
26. Adelir
27. Nsc 140865
28. Oristar Ubq
29. Q 199
30. Api-31510
31. Ube-q
32. Coenzyme Q-199
33. Bpm-31510
34. Nsc-140865
35. Bpm31510
36. Q 10aa
37. 2-((2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-yl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
38. Chebi:46245
39. Ej27x76m46
40. Ubidecarenone For System Suitability
41. Api 31510
42. Nsc-140665
43. 2-[(2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl]-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
44. Ncgc00159429-02
45. Luvacor
46. Dsstox_cid_26054
47. Dsstox_rid_81308
48. Dsstox_gsid_46054
49. (all-e)-2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione
50. 2,5-cyclohexadiene-1,4-dione, 2-((2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl
51. 2,5-cyclohexadiene-1,4-dione, 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-, (all-e)-
52. 2-((all-e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-p-benzoquinone
53. 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-p-benzoquinone
54. P-benzoquinone, 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-
55. Coq 10
56. Bio-quinon
57. Ubidecarenona
58. Ubidecarenonum
59. Ubidecarenonum [latin]
60. Coenzyme Q(sub 10)
61. Ubidecarenona [spanish]
62. Coq(sub 10)
63. Ubiquinone Q(sub 10)
64. Cas-303-98-0
65. Ccris 9016
66. Co-enzyme Q-10
67. Einecs 206-147-9
68. Co Q10
69. Unbiquinone
70. Armolipid
71. Kudesan
72. Mitocor
73. Akvion
74. Unii-ej27x76m46
75. Nsc140865
76. Liquid-q
77. Ubiquinone-q10
78. Ubidecarenone [inn:ban:jan:nf]
79. Ubiquinone(10)
80. Ncgc00095322-03
81. Kanekaq10
82. 2,5-cyclohexadiene-1,4-dione, 2-((2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-
83. 2-((2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
84. 2-[(2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-yl]-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
85. All-trans-ubiquinone
86. Li-q-sorb
87. Q-gel
88. Adelir (tn)
89. Coenzymeq10,(s)
90. Kaneka Q10
91. Mfcd00042919
92. Bp31510
93. Co Enzyme Q-10
94. Ubiquinone [inci]
95. Coq10; Ubiquinone-10
96. Coenzyme Q10(coq10)
97. Aqua Q 10l10
98. Ubidecarenone [dsc]
99. Ubidecarenone [inn]
100. Ubidecarenone [jan]
101. Ubidecarenone (jp17/inn)
102. Q-gel 100
103. Schembl19858
104. Mls000028745
105. Ubidecarenone [mart.]
106. Ubiquinone 50 [mi]
107. Voriconazole Impurity C
108. Coenzyme Q10 [vandf]
109. Ubidecarenone [usp-rs]
110. Ubidecarenone [who-dd]
111. Chembl454801
112. (non-labelled)coenzyme Q10-d5
113. Dtxsid6046054
114. Schembl11901691
115. Ex-a973
116. Coenzyme Q10, Analytical Standard
117. Hy-n0111
118. Tox21_111660
119. Tox21_113394
120. Ubidecarenone [ep Monograph]
121. Lmpr02010001
122. S2398
123. Zinc85427689
124. Coenzyme Q10, >=98% (hplc)
125. Akos015897104
126. Akos015951232
127. Ac-4352
128. Db09270
129. 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-tetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl)-5,6-dimethoxy-3-methyl-[1,4]benzoquinone
130. 2-[(2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione
131. As-13341
132. Ls-15517
133. Q 10
134. Q-10
135. Smr000058651
136. C1971
137. Cs-0007796
138. N1796
139. C-7060
140. D01065
141. 303c980
142. A936217
143. Q321285
144. Ubidecarenone For System Suitability [usp-rs]
145. Ubidecarenone, European Pharmacopoeia (ep) Reference Standard
146. Ubidecarenone, United States Pharmacopeia (usp) Reference Standard
147. 2-deca(3-methylbut-2-enylene)-5,6-dimethoxy-3-methyl-p-benzoquinone
148. Coenzyme Q10 Solution, 1 Mg/ml In Ethanol, Certified Reference Material, Ampule Of 1 Ml
149. Ubidecarenone For System Suitability, European Pharmacopoeia (ep) Reference Standard
150. Ubidecarenone For System Suitability, United States Pharmacopeia (usp) Reference Standard
151. (all-e)-2,3-dimethoxy-5-methyl-6-(3,7,11,15,19,23,27,31-octamethyl-2,6,10,14,18,22,26,30-dotriacontaoctaenyl)-2,5-cyclohexadiene-1,4-dione
152. 2,4-dione, 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-
153. 2,4-dione, 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-, (all-e)-
154. 2,5-cyclohexadiene-1,4-dione, 2-((2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl)-5,6-dimethoxy-3-methyl-
155. 2,5-cyclohexadiene-1,4-dione, 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-, (all Trans)-
156. 2-((all-e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione
157. 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-p-benzoquinone, (all Trans)-
158. 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecenyl)-5,6-dimethoxy-3-methyl-1,4-benzoquinone
159. 2-[(2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl]-5,6-dimethoxy-3-methyl- 2,5-cyclohexadiene-1,4-dione
160. 2-[(2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl]-5,6-dimethoxy-3-methylbenzo-1,4-quinone #
161. P-benzoquinone,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-
| Molecular Weight | 863.3 g/mol |
|---|---|
| Molecular Formula | C59H90O4 |
| XLogP3 | 19.4 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 31 |
| Exact Mass | 862.68391135 g/mol |
| Monoisotopic Mass | 862.68391135 g/mol |
| Topological Polar Surface Area | 52.6 Ų |
| Heavy Atom Count | 63 |
| Formal Charge | 0 |
| Complexity | 1840 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 9 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
The diet supplements containing ubidecarenone are indicated, as stated in the product label, to assist individuals with cardiovascular complaints including congestive heart failure and systolic hypertension. In the product, ubidecarenone is used to increase the cardiac input as well as for the prevention of several other diseases like Parkinson, fibromyalgia, migraine, periodontal disease and diabetes, based on preclinical studies. It is important to highlight that these products are not FDA approved and it is recommended to use under discretion.
Ubidecarenon has roles in many prysiological process including sulfide oxidation, regulation of mitochondrial permeability transition pore and translocation of protons and calcium ions accross biological membranes. Studies have shown its benefitial effect in treating cancer, statin myopathy, congestive heart failure and hypertension.
Vitamins
Organic substances that are required in small amounts for maintenance and growth, but which cannot be manufactured by the human body. (See all compounds classified as Vitamins.)
C - Cardiovascular system
C01 - Cardiac therapy
C01E - Other cardiac preparations
C01EB - Other cardiac preparations
C01EB09 - Ubidecarenone
Absorption
Ubidecarenone is absorbed from the small intestine into the lymphatics and then it can enter the blood. The hydrophobicity and large molecular weight limit its absorption making it very poor and variable depending on the food intake and the number of lipids presented in the food. The absorption is lower in the presence of an empty stomach and greater in presence of high lipid food diet. The daily dosage of ubidecarenone presents the reach of maximal serum concentration by reaching a plateau after three weeks. The pharmacokinetic properties may vary between different brands but studies have reported an AUC of 11.51 mcg h/ml and a Cmax of 0.32 mcg/ml at a time of 7.9 h.
Route of Elimination
The main elimination route of ubidecarenone is through the bile. After its oral administration, over 60% of the dose is excreted in the feces in the form of unchanged ubidecarenone and a small fraction of the metabolites. In the urine, ubidecarenone is bound to saposin B protein and represents only 8.3% of the total administered dose.
Volume of Distribution
Ubidecarenone is distributed to the various tissues of the body and it is able to enter the brain. In preclinical studies with intravenous administration of ubidecarenone, it is reported a volume of distribution of 20.4 L/kg which reflects its ability to penetrate extensively into organs and tissues. AS a general rule, tissues with high-energy requirements or metabolic activity tend to presents higher amounts of ubidecarenone, these organs can be heart, kidney, liver and muscle.
Clearance
In preclinical studies with intravenous administration of ubidecarenone, it is reported a total clearance of 1.18 ml h/kg which was indicative of a prolonged elimination.
Studies indicate that there is no saturation process during the metabolism of ubidecarenone. It is metabolized in all tissues by the phosphorylation in the cells and transportation to the kidneys for further excretion by the urine. After exerting its action, ubidecarenone is reduced and forms hydroquinone which is capable of recycling and regenerates other antioxidants such as tocopherol and ascorbate. The later metabolism of hydroquinone generates the formation of Q acid I and Q acid II in free and conjugated forms.
The pharmacokinetic properties may vary between different brands but studies have reported a half-life of ubidecarenone of 21.7 h.
Ubidecarenone is an essential cofactor in the mitochondrial electron transport chain. Its functions are the acceptance of electrons from the complex I and II and this activity is vital for the production of ATP. It acts as a mobile redox agent shuttling electrons and protons in the electron transport chain. Ubidecarenone also presents antioxidant activity in mitochondria and cellular membranes, protecting against peroxidation of lipid membranes as well as inhibiting oxidation of LDL-cholesterol.
Market Place
